Gutgesell, Robert M. http://orcid.org/0000-0001-6137-0468
Nogueiras, Rubén http://orcid.org/0000-0002-9976-9930
Tschöp, Matthias H.
Müller, Timo D. http://orcid.org/0000-0002-0624-9339
Funding for this research was provided by:
European Research Council (ERC-CoG Trusted no.101044)
Article History
Received: 9 February 2024
Accepted: 12 March 2024
First Online: 4 April 2024
Declarations
:
: Robert M. Gutgesell and Rubén Nogueiras declare that they have nothing to disclose. MHT is a member of the scientific advisory board of ERX Pharmaceuticals, Cambridge, Mass. He was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019. He attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016. He received funding for his research projects by Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). He was a consultant for Bionorica SE (2013–2017), Menarini Ricerche S.p.A. (2016), and Bayer Pharma AG Berlin (2016). As former Director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018), and since 2018, as CEO of Helmholtz Zentrum München, he has been responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide, including but not limited to pharmaceutical corporations like Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed, BioSyngen, and others. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes-related patent portfolios of Helmholtz Zentrum München as, e.g., WO/2016/188932 A2 or WO/2017/194499 A1. MHT confirms that to the best of his knowledge none of the above funding sources were involved in the preparation of this paper. TDM receives research funding from Novo Nordisk but these funds are unrelated to the work described here. TDM received speaking fees within the last 3 years from Novo Nordisk, Eli Lilly, AstraZeneca, Merck, Berlin Chemie AG, and Mercodia.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.